DiscoverBiovergeUnlocking the Potential of Genetic Medicines
Unlocking the Potential of Genetic Medicines

Unlocking the Potential of Genetic Medicines

Update: 2023-04-15
Share

Description

David Kirn, Co-Founder and CEO of 4DMT, sits down with Neil to discuss the limits of existing AAV vectors and how his company is using its Therapeutic Vector Evolution platform to invent customized vectors that allows it to take a disease specific approach to unlock the potential of genetic medicines.
Comments 
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Unlocking the Potential of Genetic Medicines

Unlocking the Potential of Genetic Medicines

The Bioverge Podcast